SCHEMBL7136553

SCHEMBL7136553

CCOC(=O)CCc1ccc(NC(=O)c2csc(NC(=O)NCc3ccccc3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
TP53 P04637 1/20 0.50
MAPT P10636 5/20 0.49
NAMPT P43490 1/20 0.49
RAB9A P51151 4/20 0.48
NPC1 O15118 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ROCK2 O75116 2/20 0.47
ROCK1 Q13464 2/20 0.47
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 3/20 0.46
PPID Q08752 2/20 0.46
PARP1 P09874 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
EGFR P00533 1/20 0.44
KDR P35968 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27490613 0.91 ROCK2 (0.50) LMNAMAPTNAMPTRAB9ANPC1
SCHEMBL7145773 0.87 ROCK2 (0.53) LMNAMAPTNAMPTRAB9ANPC1
SCHEMBL7147820 0.86 LMNA (0.48) LMNATP53MAPTNAMPTRAB9A
SCHEMBL7138772 0.86 MAPT (0.49) LMNATP53MAPTNAMPTRAB9A
SCHEMBL7143549 0.85 LMNA (0.46) LMNATP53MAPTNAMPTRAB9A
SCHEMBL6881918 0.85 MAPT (0.47) LMNATP53MAPTNAMPTRAB9A
SCHEMBL15145661 0.84 PPID (0.60) LMNATP53MAPTNAMPTRAB9A
SCHEMBL7138766 0.83 LMNA (0.44) LMNATP53MAPTNAMPTRAB9A
SCHEMBL7537521 0.82 MAPT (0.47) LMNATP53MAPTNAMPTRAB9A
SCHEMBL7142027 0.81 PPID (0.48) LMNATP53MAPTNAMPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US claimed
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 LMNA 3184/4885TP53 525/4885MAPT 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.